Özlem Türeci, MDChair of CI3 and Head of Clinical & Scientific Advisors Board at BioNTech
Özlem Türeci is an MD with over 25 years of expertise in cancer research and immune oncology. Özlem is one of the scientists behind the Biotech companies Ganymed and Biontech. Until Ganymed was acquired by Astellas in 2016 she was Chief Executive Officer of the company and led the development of novel mAbs against solid cancers. In Biontech she acted as Chair of the Scientific and Clinical Advisory Board since inception of the company. Furthermore, she is an executive board member of CIMT, the largest European Association for Cancer Immunotherapy, and Chair of the CI3 cluster initiative. Özlem is inventor on more than 200 international patent applications and granted patents, and authored more than 110 articles in peer-reviewed scientific journals.